IVIG Delays Onset in a Mouse Model of Gerstmann-Sträussler-Scheinker Disease.

doi:10.1007/s12035-018-1228-0

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

IVIG Delays Onset in a Mouse Model of Gerstmann-Sträussler-Scheinker Disease.

Molecular neurobiology - 1 Apr 2019

Gu Huiying, Kirchhein Yvonne, Zhu Timothy, Zhao Gang, Peng Hongjun, Du Eileen, Liu Junyi, Mastrianni James A, Farlow Martin R, Dodel Richard, Du Yansheng

Abstract excerpt

Our previous studies showed that intravenous immunoglobulin (IVIG) contained anti-Aβ autoantibodies that might be able to treat Alzheimer's disease (AD). Recently, we identified and characterized naturally occurring autoantibodies against PrP from IVIG. Although autoantibodies in IVIG blocked PrP fibril formation and PrP neurotoxicity in vitro, it remained unknown whether IVIG could reduce amyloid plaque...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Progression
Share to Gerstmann-Straussler-Scheinker Disease
Share to Immunoglobulins, Intravenous

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Kaplan-Meier Estimate

Share to Neuroglia

Share to Neurons

Share to Plaque, Amyloid

Share to Prion Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 30027340
DOI: 10.1007/s12035-018-1228-0
PMCID: PMC6594182

Genes

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.